A co-located event at ISPOR Europe 2024
This summit will cover latest developments in use of real world evidence across regulatory-HTA-payer decision-making continuum with focus on methods, data transportability, and infrastructure. Major methods topics to be covered include causal inference and external control arms for comparative effectiveness analyses, the hierarchy of RWE studies, and the role of patient registries. Use of RWE in Joint Clinical Assessment of the EU HTA regulation will be explored, also with insights from the cross-border collaborations on pricing and reimbursement in the EU countries. Finally, feasibility of HTA reassessment post market entry will be considered, drawing from lessons learned from US Medicare Drug Price Negotiation.